ZINC MONOCARBONATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	CO3.Zn
Molecular Weight	125.418
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Zn++].[O-]C([O-])=O

InChI

InChIKey=FMRLDPWIRHBCCC-UHFFFAOYSA-L

InChI=1S/CH2O3.Zn/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2

HIDE SMILES / InChI

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CO3
Molecular Weight	60.0089
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttp://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303
Curator's Comment: description was created based on several sources, including https://www.drugs.com/dosage/zinc-sulfate.html | https://www.ncbi.nlm.nih.gov/pubmed/10721938 | https://www.drugbank.ca/drugs/DB01593 | https://www.ncbi.nlm.nih.gov/pubmed/17132019

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 41 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 8504
respiratory burst 39 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1447
transformed cell apoptotic process 104 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1447
Methotrexate 38 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 38
ultraviolet B-induced damage 38 Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 323
T cell mediated immunity 40 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1447
Zinc transporter ZIP1 38 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1076
Zinc transporter ZIP2 38 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 1076

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Unknown 2596
Unknown 2596
Caries 43 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 125 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 8583	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date 1955
Zinc deficiency 39 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 141 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 8583	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 2012
Diaper dermatitis 38 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 8583	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 2006
Poison Ivy dermatitis 38 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 8583	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 94 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 8583	ZINC SULFATE Approved Use Unknown Launch Date 1987
Mucositis 39 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 665	ZINC SULFATE Approved Use Unknown Launch Date 1987
Dysgeusia 38 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 665	ZINC SULFATE Approved Use Unknown Launch Date 1987
Unknown 2596

PubMed

Title	Date	PubMed
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.	1991 Apr 1	9996367
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.	1991 Sep 10	1888732
Iron chelators as therapeutic agents against Pneumocystis carinii.	1994 May	8067783
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.	1999 May	10327022
Inhibition of HIV-1 infection by zinc group metal compounds.	1999 Sep	10517314
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.	2002 Mar 1	11877378
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.	2004	16145958
Thermotoga maritima-Escherichia coli chimeric topoisomerases. Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis.	2004 Jul 16	15140883
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.	2004 Jul 16	15131129
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.	2004 Jul 30	15161915
High-throughput computational and experimental techniques in structural genomics.	2004 Oct	15489337
Impact of the mother's zinc deficiency on the woman's and newborn's health status.	2005	16240669
Erythrocyte zinc content in critically ill patients.	2005	16176172
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections].	2005	15901979
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.	2005 Apr 27	15857667
Zinc in attention-deficit/hyperactivity disorder.	2005 Aug	16190793
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.	2005 Aug	16042674
[Reduced thymulin production during occupational exposure to lead].	2005 Jan-Mar	15915658
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.	2005 May	15883427
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.	2005 Nov-Dec	16277018
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.	2005 Sep 1	16118778
Effects of zinc supplementation in patients with type 1 diabetes.	2005 Summer	16034148
Characterization and inhibition of SARS-coronavirus main protease.	2006	16611148
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.	2006 Apr	16608609
Copper and zinc concentrations in serum of healthy Greek adults.	2006 Apr 15	15955548
Effect of end-stage renal disease and diabetes on zinc and copper status.	2006 Jul	16943612
Elevated cortical zinc in Alzheimer disease.	2006 Jul 11	16832080
The effect of Ramadan on maternal nutrition and composition of breast milk.	2006 Jun	16732795
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.	2006 May	16757839
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.	2006 May	16636303
Zinc homeostasis in aging: two elusive faces of the same "metal".	2006 Summer	16706668
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.	2010 Dec 1	20851137
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.	2010 Feb	19755143
Glucarpidase following high-dose methotrexate: update on development.	2010 Jan	19925307
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.	2010 Oct	20708676
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.	2011 Jul	21481475
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.	2011 Nov 30	21974847
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.	2012 Feb	22112499
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.	2012 Feb	21964423
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.	2012 Mar	22137962
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.	2013 Dec	23519475
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.	2013 Jan	22083529
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.	2016 Mar 5	26561748
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.	2016 Oct	27248459
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.	2016 Oct 1	27546855
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.	2016 Sep	26892107

Patents

Sample Use Guides

In Vivo Use Guide

single intravenous injection of 50 Units per kg

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:55:25 GMT 2025` Edited by `admin` on `Mon Mar 31 21:55:25 GMT 2025`
Record UNII	K8290PTQ4F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZINC MONOCARBONATE

Systematic Name

English

C.I. 77950

Preferred Name

English

CI 77950

Common Name

English

ZINC CARBONATE (1:1)

Systematic Name

English

ZINC CARBONATE [MI]

Common Name

English

ZINC MONOCARBONATE [HSDB]

Common Name

English

CARBONIC ACID, ZINC SALT (1:1)

Systematic Name

English

Classification Tree Code System Code

CFR

21 CFR 177.1350